Current status of isolated limb infusion with mild hyperthermia for melanoma

References

• Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004; 150: 179–185
   PubMed Web of Science ®Google Scholar
• Lingam MK, Byrne DS, Aitchison T, MacKie RM, McKay AJ. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996; 32A: 1668–1673
   PubMed Web of Science ®Google Scholar
• Rossi CR, Foletto M, Vecchiato A, Alessio S, Menin N, Lise M. Management of cutaneous melanoma M0: State of the art and trends. Eur J Cancer 1997; 33: 2302–2312
   PubMed Web of Science ®Google Scholar
• Coit DG. Recurrent regional metastases and their management. Cutaneous melanoma, CM Balch, AN Houghton, AJ Sober, SJ Soong. Quality Medical Publishing, St Louis 1998; 301–309
   Google Scholar
• McKay A, Byrne DS. Recurrent limb melanoma: Treatments other than isolated limb perfusion and infusion. Textbook of melanoma, JF Thompson, DL Morton, BB Kroon. Martin Dunitz, London 2004; 410–428
   Google Scholar
• Creech O, Jr., Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616–632
   PubMed Web of Science ®Google Scholar
• Thompson JF, de Wilt JH. Isolated limb perfusion in the management of patients with recurrent limb melanoma: An important but limited role. Ann Surg Oncol 2001; 8: 564–565
   PubMed Web of Science ®Google Scholar
• Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Reg Cancer Treat 1994; 7: 188–192
   Google Scholar
• Thompson JF, Kam PCA, de Wilt JHW, Lindner P. Isolated limb infusion for melanoma. Textbook of melanoma, JF Thompson, DL Morton, BB Kroon. Martin Dunitz, London 2004; 429–437
   Google Scholar
• Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: A simple alternative to isolated limb perfusion. Can J Surg 2001; 44: 189–192
   PubMed Web of Science ®Google Scholar
• Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13: 1123–1129
   PubMed Web of Science ®Google Scholar
• Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905–910
   PubMedGoogle Scholar
• Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994; 4 Suppl.1: 45–50
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 1996; 83: 1319–1328
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, Mondovi B, Moricca G, Rossi-Fanelli A. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20: 1351–1381
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991; 20: 287–289
   PubMed Web of Science ®Google Scholar
• Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995; 15: 219–223
   PubMed Web of Science ®Google Scholar
• Thompson JF, Ramzan I, Kam PCA, Yau DF. Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Reg Cancer Treat 1996; 9: 13–16
   Google Scholar
• Parsons PG, Carter FB, Morrison L, Regius Mary S. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 1981; 41: 1525–1534
   PubMed Web of Science ®Google Scholar
• Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238–247
   PubMed Web of Science ®Google Scholar
• Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9: 127–136
   PubMed Web of Science ®Google Scholar
• Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: A reflection of tumor biology. Ann Surg 2007; 245: 591–596
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Thompson JF, de Wilt JH, Doubrovsky A, de Faria Lima R, Kam PC. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004; 30: 1107–1112
   PubMed Web of Science ®Google Scholar
• Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 2004; 188: 532–537
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Ueno T, Abdel-Wahab O, Cheng TY, Pruitt SK, Michael Colvin O, Freidman HS, Tyler DS. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004; 136: 210–218
   PubMed Web of Science ®Google Scholar
• Hannay J, Davis JJ, Yu D, Liu J, Fang B, Pollock RE, Lev D. Isolated limb perfusion: A novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther 2007; 14(8)671–681
   PubMed Web of Science ®Google Scholar
• Naik AM, Chalikonda S, McCart JA, Xu H, Guo ZS, Langham G, Gardner D, Mocellin S, Lokshin AE, Moss B, et al. Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum Gene Ther 2006; 17: 31–45
   PubMed Web of Science ®Google Scholar
• Damian DL, Barnetson RS, Rose BR, Bonenkamp JJ, Thompson JF. Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin D. Australas J Dermatol 2001; 42: 106–109
   PubMedGoogle Scholar
• Damian DL, Barnetson RS, Thompson JF. Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg 2006; 10: 48–51
   PubMed Web of Science ®Google Scholar
• Elhassadi E, Egan E, O'Sullivan G, Mohamed R. Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. Clin Lab Haematol 2006; 28: 279–281
   PubMedGoogle Scholar
• van Ginkel RJ, Thijssens KM, Pras E, van der Graaf WT, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: Three time periods at risk for amputation. Ann Surg Oncol 2007; 14: 1499–1506
   PubMed Web of Science ®Google Scholar
• Thompson JF, Kam PCA, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238–247
   PubMed Web of Science ®Google Scholar
• Lindner P, Thompson JF, De Wilt JH, Colman M, Kam PC. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 2004; 30: 433–439
   PubMed Web of Science ®Google Scholar